연구성과로 돌아가기
2020 연구성과별 연구자 정보 (64 / 2428)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Hann, Hie-Won | Hann, HW | 22 | Thomas Jefferson Univ Hosp, Div Gastroenterol & Hepatol, Philadelphia, PA USA | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Agarwal, Kosh | Agarwal, K | 23 | Kings Coll Hosp London, Inst Liver Studies, London, England | ABH-8721-2020 | Agarwal, Kosh | pietro.lampertico@unimi.it; | |||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Lim, Young-Suk | Lim, YS | 24 | Univ Ulsan, Ctr Liver, Asan Med Ctr, Dept Gastroenterol,Coll Med, Ulsan, South Korea | AFQ-5165-2022 | Lim, Young-Suk | pietro.lampertico@unimi.it; | |||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Lim, Young-Suk | Lim, YS | 24 | Chinese Univ Hong Kong, Dept Med & Therapeut, Inst Digest Dis, Hong Kong, Peoples R China | AFQ-5165-2022 | Lim, Young-Suk | pietro.lampertico@unimi.it; | |||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Chan, Henry | Chan, H | 25 | Chinese Univ Hong Kong, Dept Med & Therapeut, Inst Digest Dis, Hong Kong, Peoples R China | B-9636-2008 | Chan, Henry | pietro.lampertico@unimi.it; | |||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Chan, Henry | Chan, H | 25 | Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China | B-9636-2008 | Chan, Henry | pietro.lampertico@unimi.it; | |||
| A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chen, Li-Tzong | Chen, LT | 1 | Natl Cheng Kung Univ, Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan | nboku@ncc.go.jp; | |||||
| A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chen, Li-Tzong | Chen, LT | 1 | Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan | nboku@ncc.go.jp; | |||||
| A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Satoh, Taroh | Satoh, T | 2 | Osaka Univ, Frontier Sci Canc & Chemotherapy, Grad Sch Med, Suita, Osaka, Japan | AAF-7913-2020 | Satoh, Taroh | nboku@ncc.go.jp; | |||
| A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Ryu, Min-Hee | Ryu, MH | 3 | Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea | nboku@ncc.go.jp; | |||||
| A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chao, Yee | Chao, Y | 4 | Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan | nboku@ncc.go.jp; | |||||
| A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Kato, Ken | Kato, K | 5 | Natl Canc Ctr, Div Gastrointestinal Med Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo, Japan | nboku@ncc.go.jp; | |||||
| A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chung, Hyun Cheol | Chung, HC | 6 | Yonsei Univ, Yonsei Univ Hlth Syst, Song Dang Inst Canc Res, Div Med Oncol,Yonsei Canc Ctr,Coll Med, Seoul, South Korea | AFB-8969-2022 | Chung, Hyun Cheol | 0000-0002-0920-9471 | Chung, Hyun | nboku@ncc.go.jp; | |
| A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chen, Jen-Shi | Chen, JS | 7 | Chang Gung Univ, Linkou Chang Gung Mem Hosp, Dept Internal Med, Div Hematol & Oncol, Taoyuan, Taiwan | GLV-3349-2022 | Chen, Jen-Shi | nboku@ncc.go.jp; | |||
| A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Muro, Kei | Muro, K | 8 | Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan | nboku@ncc.go.jp; |
페이지 이동: